Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 8, 2022

Primary Completion Date

August 31, 2025

Study Completion Date

February 28, 2027

Conditions

Malignant Epithelial Neoplasms

Interventions

BIOLOGICAL

TCR-transduced T cells

TSA-reactive TCR-engineered T cells

DRUG

CDX-1140

Recombinant fully human IgG2κ monoclonal antibody

DRUG

Pembrolizumab

Humanized immunoglobulin G4 (IgG4) monoclonal antibody

Trial Locations (1)

Providence Portland Medical Center, Portland

All Listed Sponsors

lead

Providence Health & Services

OTHER